MOR 201
Latest Information Update: 01 Aug 2024
At a glance
- Originator MorphoSys; ProChon Biotech
- Developer MorphoSys
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Fibroblast growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 31 Jul 2003 Discontinued - Preclinical for Haematological malignancies in Germany (unspecified route)
- 27 Jun 2003 MOR 201 is available for licensing (http://www.morphosys.com)
- 02 May 2002 Preclinical trials in Haematological malignancies in Germany (unspecified route)